Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care
Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.
Innovation, Affordability, Access: Alzheimer Disease Drugs and the Inflation Reduction Act
The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
